EUVIMEDEUVIMED entdecken
Open Access

Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria

A Senhaji-Kacha, A Akir, A Broncano-Lavado, J Esteban

Revista Española de Quimioterapia · 2024

DOI: 10.37201/req/014.2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Española de Quimioterapia, 2024. Verfasst von A Senhaji-Kacha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Jaime Esteban, MD, PhD.Department of ClinicalMicrobiology. IIS-Fundación Jiménez Díaz. Av. Reyes Católicos, 2. 28040-Madrid, Spain. jestebanmoreno@gm…. Hauptthemen laut MEDLINE: Clarithromycin, Biofilms, Anti-Bacterial Agents, Nontuberculous Mycobacteria. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mycobacterium avium complex (MAC) and Mycobacterium abscessus are a group of nontuberculous mycobacteria (NTM) that have been described as human pathogens. Their ability to develop biofilms in tissues and medical devices is one of the most important pathogenicity factors, with important implications in diagnosis and treatment. Macrolides are usually considered one of the bases of this treatment.

Methods

Here we have studied the biofilm prevention concentration (BPC) of 16 strains (n=16) with clarithromycin to avoid the biofilm development by these NTM.

Results

In this study, all M. abscessus strains have similar BPC, while MAC strains showed different values. For MAC the concentrations ranged between 1-16 mg/L, while for M. abscessus the concentration was 32 mg/L for all strains except one that was 64 mg/L.

Conclusions

These results open the possibility of using macrolides for the prevention of biofilm development in patients with a risk of developing NTM disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClarithromycinBiofilmsAnti-Bacterial AgentsNontuberculous MycobacteriaMicrobial Sensitivity TestsHumansMycobacterium Infections, NontuberculousMycobacterium avium ComplexMycobacterium abscessus

Stichwörter der Autor:innen

BPCMICMycobacterium abscessusMycobacterium aviumbiofilm preventionclarithromycinnontuberculous mycobacteria

Substanzen

ClarithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Jaime Esteban, MD, PhD.Department of ClinicalMicrobiology. IIS-Fundación Jiménez Díaz. Av. Reyes Católicos, 2. 28040-Madrid, Spain. jestebanmoreno@gmial.com; jesteban@fjd.es.

Zitieren

APA

Senhaji-Kacha, A., Akir, A., Broncano-Lavado, A., & Esteban, J. (2024). Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria. Revista Española de Quimioterapia. https://doi.org/10.37201/req/014.2024

Vancouver

Senhaji-Kacha A, Akir A, Broncano-Lavado A, Esteban J. Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria. Revista Española de Quimioterapia. 2024. doi:10.37201/req/014.2024

BibTeX
@article{SenhajiKacha2024,
  author = {Senhaji-Kacha, A and Akir, A and Broncano-Lavado, A and Esteban, J},
  title = {Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria},
  journal = {Revista Española de Quimioterapia},
  year = {2024},
  doi = {10.37201/req/014.2024}
}
Kostenlos starten →